Literature DB >> 23298949

Nomograms to predict risk of in-hospital and post-discharge venous thromboembolism after abdominal and thoracic surgery: an American College of Surgeons National Surgical Quality Improvement Program analysis.

Dhruvil R Shah1, Hui Wang, Richard J Bold, Xiaowei Yang, Steve R Martinez, Anthony D Yang, Vijay P Khatri, David H Wisner, Robert J Canter.   

Abstract

BACKGROUND: Postoperative venous thromboembolism (VTE) is increasingly viewed as a quality of care metric, although risk-adjusted incident rates of postoperative VTE and VTE after hospital discharge (VTEDC) are not available. We sought to characterize the predictors of VTE and VTEDC to develop nomograms to estimate individual risk of VTE and VTEDC.
METHODS: Using the American College of Surgeons National Surgical Quality Improvement Program database, we identified 471,867 patients who underwent inpatient abdominal or thoracic operations between 2005 and 2010. We excluded primary vascular and spine operations. We built logistic regression models using stepwise model selection and constructed nomograms for VTE and VTEDC with statistically significant covariates.
RESULTS: The overall, unadjusted, 30-d incidence of VTE and VTEDC was 1.5% and 0.5%, respectively. Annual incidence rates remained unchanged over the study period. On multivariate analysis, age, body mass index, presence of preoperative infection, operation for cancer, procedure type (spleen highest), multivisceral resection, and non-bariatric laparoscopic surgery were significant predictors for VTE and VTEDC. Other significant predictors for VTE, but not VTEDC, included a history of chronic obstructive pulmonary disease, disseminated cancer, and emergent operation. We constructed and validated nomograms by bootstrapping. The concordance indices for VTE and VTEDC were 0.77 and 0.67, respectively.
CONCLUSIONS: Substantial variation exists in the incidence of VTE and VTEDC, depending on patient and procedural factors. We constructed nomograms to predict individual risk of 30-d VTE and VTEDC. These may allow more targeted quality improvement interventions to reduce VTE and VTEDC in high-risk general and thoracic surgery patients.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23298949     DOI: 10.1016/j.jss.2012.12.016

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  5 in total

1.  Risk factors for venous thromboembolism and evaluation of the modified Caprini score in patients undergoing lung resection.

Authors:  Songping Cui; Shuo Chen; Hui Li; Lihui Ke; Yi Liu; Ruiheng Jiang; Bin Hu; Tong Li; Yang Wang; Jinbai Miao; Wenqian Zhang
Journal:  J Thorac Dis       Date:  2020-09       Impact factor: 2.895

2.  Effectiveness of intraoperative administration of intermittent pneumatic compression in preventing deep vein thrombosis in lung cancer patients undergoing video-assisted thoracoscopic surgery lobectomy.

Authors:  Xiaojun Wang; Saiqi Song; Ruijie Ni; Min Lu; Yanjun Mao
Journal:  J Thorac Dis       Date:  2019-07       Impact factor: 2.895

3.  Derivation and validation of a nomogram model for pulmonary thromboembolism in patients undergoing lung cancer surgery.

Authors:  Yuping Li; Lei Shen; Junrong Ding; Dong Xie; Jian Yang; Yanfeng Zhao; Angelo Carretta; René Horsleben Petersen; Sebastien Gilbert; Yasuhiro Hida; Servet Bölükbas; Hiran C Fernando; Gening Jiang; Yuming Zhu
Journal:  Transl Lung Cancer Res       Date:  2021-04

4.  Prediction Model of in-Hospital Venous Thromboembolism in Chinese Adult Patients after Hernia Surgery: The CHAT Score.

Authors:  Zhi-Chun Gu; Chi Zhang; Ya Yang; Ming-Gang Wang; Hang-Yu Li; Guang-Yong Zhang
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

5.  A postdischarge venous thromboembolism risk calculator for inflammatory bowel disease surgery.

Authors:  Cary Jo R Schlick; Tarik K Yuce; Anthony D Yang; Michael F McGee; David J Bentrem; Karl Y Bilimoria; Ryan P Merkow
Journal:  Surgery       Date:  2020-10-17       Impact factor: 3.982

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.